«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

28卷

期数:

2022年06期

页码:

577-584

栏目:

生物信息学专题

出版日期:

2022-11-20

文章信息/Info

Title:

Expression and clinical value of PTX3 gene in breast cancer based on bioinformatics analysis

文章编号:

1006-8147(2022)06-0577-08

作者:

赵雅雯; 马勇杰

天津医科大学肿瘤医院肿瘤细胞生物学实验室，国家肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津市“肿瘤防治”重点实验室，天津 300060

Author(s):

ZHAO Ya-wen; MA Yong-jie

（Cancer Cell Biology Laboratory，Cancer Institute and Hospital，Tianjin Medical University，National Clinical Research Center for Cancer；Tianjin′s Clinical Research Center for Cancer；Key Laboratory of Breast Cancer Prevention and Therapy，Ministry of Education；Key Laboratory of Cancer Prevention and Therapy，Tianjin 300060，China）

关键词:

乳腺癌; PTX3; 生物信息; 基因表达

Keywords:

breast cancer; PTX3;  biological information;  gene expression

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：通过分析生物信息数据库相关资料，探究五聚蛋白3（PTX3）基因在乳腺癌中的表达和临床意义。方法：利用TIMER数据库和GEPIA2.0数据库对PTX3 mRNA在正常乳腺组织和乳腺癌组织中的表达进行分析；利用UALCAN数据库和Kaplan-Meier Plotter数据库分析PTX3与乳腺癌临床特征和预后的关系；利用STRING数据库构建PTX3蛋白相互作用网络；利用CancerSEA 数据库分析PTX3基因与乳腺癌单个细胞功能状态的相关性。结果：TIMER和GEPIA2.0在线平台分析结果显示，与正常乳腺组织相比，PTX3 mRNA在乳腺癌组织中低表达。UALCAN数据库分析结果显示，PTX3 mRNA表达与年龄、TNM分期、淋巴结转移数、TP53突变有关。Kaplan-Meier Plotter数据库分析结果显示，PTX3 mRNA高表达的乳腺癌患者的总体生存期（HR=0.8，95%CI：0.65～0.97，P=0.026）和无进展生存期（HR=0.89，95%CI：0.8～0.99，P=0.032）更长。在Luminal A型、基底样型乳腺癌患者中，PTX3 mRNA高表达的人群总生存期更长。同时，在Luminal A型、基底样型以及Luminal B型乳腺癌患者中，PTX3 mRNA高表达的人群无进展生存期更长；STRING蛋白相互作用网络分析显示，PTX3蛋白相互作用网络包括FGF2、FCN1、CFH、FCN2、TNFAIP6、SELP、MBL2、C1QA、CFHR1主要参与免疫调节作用以及炎症，部分蛋白可调节细胞存活、细胞分裂、血管生成、细胞分化和细胞迁移。CancerSEA数据库分析结果显示，PTX3基因的表达与炎症反应呈显著正相关（P<0.001），与转移、干细胞特性、组织缺氧呈显著负相关（均P<0.001）。结论：PTX3在乳腺癌组织中低表达，与年龄、肿瘤分级、淋巴结转移数、TP53突变相关，且PTX3 mRNA高表达乳腺癌患者生存预后较好，主要参与免疫调节作用以及炎症、调节细胞存活、细胞分裂、血管生成、细胞分化和细胞迁移等。

Abstract:

Objective： To investigate the expression and clinical significance of Pentraxin 3（PTX3） gene in breast cancer based on bioinformatics database analysis. Methods：The expression of PTX3 mRNA in normal tissues and breast cancer tissues was analyzed by using TIMER database and GEPIA2.0 database.UALCAN database and Kaplan-Meier Plotter database were used to analyze the relationship between PTX3 and clinical features and prognosis of breast cancer. PTX3 protein interaction network was constructed using STRING database. CancerSEA database was used to analyze the correlation between PTX3 gene and functional status of single breast cancer cells. Results：The results of TIMER and GEPIA2.0 online platform analysis showed that PTX3 mRNA level was lower in breast cancer tissues compared with normal breast tissues. UALCAN database analysis showed that PTX3 mRNA expression was related to age，TNM stages，number of lymph node metastases and TP53 mutation. Kaplan-Meier Plotter database analysis results showed that overall survival（HR=0.8，95%CI：0.65-0.97，P=0.026） and progression-free survival（HR=0.89，95%CI：0.8-0.99，P=0.032） in breast cancer patients with high PTX3 expression was better.Luminal A type and basal like type breast cancer patients with high expression of PTX3 mRNA had better overall survival prognosis. Meanwhile，in Luminal A type，basal like type and Luminal B type，patients with high PTX3 mRNA expression had longer progression free survival. STRING protein interaction network analysis showed that PTX3 protein interaction network including FGF2，FCN1，CFH，FCN2，TNFAIP6，SELP，MBL2，C1QA and CFHR1. They were mainly involved in immune regulation and inflammatory response，and some proteins regulate cell survival，cell division，angiogenesis，cell differentiation and cell migration. CancerSEA database analysis showed that PTX3 gene expression was significantly positively correlated with inflammatory response（P<0.001），and significantly negatively correlated with metastasis，stem cell characteristics，and tissue hypoxia，respectively（all P<0.001）. Conclusion：The expression of PTX3 is decreased in breast cancer，which is related to age，tumor grade，number of lymph node metastasis and TP53 mutation.The survival prognosis of breast cancer patients with high expression of PTX3 mRNA is better. PTX3 is mainly involved in immunomodulatory effect，inflammatory response，regulation of cell survival，cell division，angiogenesis，cell differentiation and cell migration.

参考文献/References:

[1] BRAY F，FERLAY J，SOERJOMATARAM I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] HARBECK N，GNANT M. Breast cancer[J]. Lancet，2017，389（10074）：1134-1150.
[3] REDIG A J，MCALLISTER S S. Breast cancer as a systemic disease：a view of metastasis[J]. J Intern Med，2013，274（2）：113-126.
[4] DONI A，STRAVALACI M，INFORZATO A，et al. The long pentraxin PTX3 as a link between innate immunity，tissue remodeling，and cancer[J]. Front Immunol，2019，10：712.
[5] GARLANDA C，BOTTAZZI B，MAGRINI E，et al. PTX3，a humoral pattern recognition molecule，in innate immunity，tissue repair，and cancer[J]. Physiol Rev，2018，98（2）：623-639.
[6] BOTTAZZI B，DONI A，GARLANDA C，et al. An integrated view of humoral innate immunity：pentraxins as a paradigm[J]. Annu Rev Immunol，2010，28：157-183.
[7] BONFIGLIO R，SCIMECA M，TOSCHI N，et al. Radiological，histological and chemical analysis of breast microcalcifications：diagnostic value and biological significance[J]. J Mammary Gland Biol Neoplasia，2018，23（1/2）：89-99.
[8] SCIMECA M，ANTONACCI C，COLOMBO D，et al. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers[J]. Tumour Biol，2016，37（4）：5427-5435.
[9] LI T，FAN J，WANG B，et al.TIMER：a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res，2017，77（21）：e108-e110.
[10] TANG Z，LI C，KANG B，et al. GEPIA：a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res，2017，45（W1）：W98-W102.
[11] HOU G X，LIU P，YANG J，et al. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter[J]. PLoS One，2017，12（3）：e0174515.
[12] CHANDRASHEKAR D S，BASHEL B，BALASUBRAMANYA S A H，et al. UALCAN：aportal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia，2017，19（8）：649-658.
[13] SZKLARCZYK D，GABLE A L，NASTOU K C，et al. The STRING database in 2021：customizable protein-protein networks，and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res，2021，49（D1）：D605-D612.
[14] YUAN H，YAN M，ZHANG G，et al. CancerSEA：a cancer single-cell state atlas[J]. Nucleic Acids Res，2019，47（D1）：D900-D908.
[15] VON MERING C，HUYNEN M，JAEGGI D，et al. STRING：a database of predicted functional associations between proteins[J]. Nucleic Acids Res，2003，31（1）：258-261.
[16] A M B，R V S，J M E，et al. Breast cancer biomarkers：risk assessment，diagnosis，prognosis，prediction of treatment efficacy and toxicity，and recurrence[J]. Curr Pharm Des，2014，20（30）：4879-4898.
[17] BONAVITA E，MANTOVANI A，GARLANDA C. PTX3 acts as an extrinsic oncosuppressor[J]. Oncotarget，2015，6（32）：32309-32310.
[18] RUBINO M，KUNDERFRANCO P，BASSO G，et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer[J]. Oncoimmunology，2017，6（7）：e1333215.
[19] MATARAZZO S，MELOCCHI L，REZZOLA S，et al. Long pentraxin-3 follows and modulates bladder cancer progression[J].Cancers（Basel），2019，11（9）：1277.
[20] MANTOVANI A，ALLAVENA P，SICA A，et al. Cancer-related inflammation[J]. Nature，2008，454（7203）：436-444.
[21] COUSSENS L M，WERB Z. Inflammation and cancer[J]. Nature，2002，420（6917）：860-867.
[22] AHMMED B，KAMPO S，KHAN M，et al. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent，NF-kappaB- and HIF-1alpha-mediated downregulation of PTX3[J]. J Cell Physiol，2019，234（7）：10680-10697.
[23] CUI X，ZHANG H，CAO A，et al. Cytokine TNF-alpha promotes invasion and metastasis of gastric cancer by down-regulating Pentraxin3[J]. J Cancer，2020，11（7）：1800-1807.
[24] RONCA R，DI SALLE E，GIACOMINI A，et al. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells[J]. Mol Cancer Ther，2013，12（12）：2760-2771.
[25] WANG Z，WANG X，ZOU H，et al. The basic characteristics of the pentraxin family and their functions in tumor progression[J]. Front Immunol，2020，11：1757.
[26] RONCA R，ALESSI P，COLTRINI D，et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer[J]. J Pathol，2013，230（2）：228-238.
[27] BASILE A，MOSCHETTA M，DITONNO P，et al. Pentraxin 3 （PTX3） inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients[J]. J Pathol，2013，229（1）：87-98.

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(06):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(06):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(06):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(06):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(06):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(06):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(06):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(06):466.
[11]贾圣陶,赵雅雯,王克朕,等.Pentraxin 3蛋白在乳腺癌中的表达及其临床意义[J].天津医科大学学报,2021,27(05):515.
　JIA Sheng-tao,ZHAO Ya-wen,WANG Ke-zhen,et al.The expression and clinical significance of Pentraxin 3 in breast cancer[J].Journal of Tianjin Medical University,2021,27(06):515.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金（82172987）
作者简介 赵雅雯（1989-），女，药士，学士，研究方向：肿瘤学；
通信作者：马勇杰，E-mail：mayongjie@tjmuch.com。

常用功能

更新日期/Last Update: 2022-11-20